

Carlos V P Jardim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7384403/publications.pdf>

Version: 2024-02-01

51
papers

1,175
citations

448610

19
h-index

445137

33
g-index

55
all docs

55
docs citations

55
times ranked

1371
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-3.	0.8	4
2	Electrical impedance tomography in pulmonary arterial hypertension. <i>PLoS ONE</i> , 2021, 16, e0248214.	1.1	6
3	Atualiza�o no Tratamento da Hipertens�o Arterial Pulmonar. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 750-764.	0.3	6
4	Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. <i>PLoS ONE</i> , 2020, 15, e0233063.	1.1	10
5	Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension. <i>Clinics</i> , 2020, 75, e1373.	0.6	3
6	Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. <i>Jornal Brasileiro De Pneumologia</i> , 2020, 46, e20200204-e20200204.	0.4	3
7	Cancer-associated thrombosis: the when, how and why. <i>European Respiratory Review</i> , 2019, 28, 180119.	3.0	160
8	The global view. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 391-397.	1.2	3
9	Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180297.	0.4	7
10	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2018, 51, 1800307.	3.1	16
11	Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. <i>Clinics</i> , 2018, 73, e216.	0.6	19
12	Reperfusion in acute pulmonary thromboembolism. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 237-243.	0.4	9
13	The importance of the World Symposium on Pulmonary Hypertension. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 173-174.	0.4	3
14	Pulmonary hypertension in lymphangiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 74.	1.2	34
15	3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 109, 1-104.	0.3	21
16	The use of new anticoagulants in CTEPH. , 2017, , .		0
17	Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension. , 2017, , .		0
18	Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2015, 15, 118.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Pulmonary Arterial Hypertension in the Southern Hemisphere. Chest, 2015, 147, 495-501.	0.4	54
20	Epidemiology and Disease Classification of Pulmonary Hypertension. Respiratory Medicine, 2015, , 21-35.	0.1	1
21	Biomarkers and Prognostic Indicators in Pulmonary Arterial Hypertension. Current Hypertension Reports, 2015, 17, 556.	1.5	8
22	Prognostic value of predicted 6MWD in PAH. , 2015, , .		0
23	Quality of life as a prognostic marker in pulmonary arterial hypertension. Health and Quality of Life Outcomes, 2014, 12, 130.	1.0	40
24	Goal-oriented treatment of pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2014, 20, 409-413.	1.2	3
25	Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. Journal of Infection, 2014, 68, 90-98.	1.7	33
26	Skeletal Muscle Abnormalities in Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e114101.	1.1	41
27	Idiopathic Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 560-567.	0.8	11
28	Biomarkers in Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 59-64.	0.1	0
29	The Role of Target Therapies in Schistosomiasis-Associated Pulmonary Arterial Hypertension. Chest, 2012, 141, 923-928.	0.4	48
30	Safety and efficacy of sitaxsentan 50 and 100Âmg in patients with pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2012, 25, 33-39.	1.1	32
31	Schistosomiasis and Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 143-148.	0.1	2
32	The Role Of Target-Therapies In Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , .		0
33	Comparative Analysis Of The Immunopathology In Idiopathic Versus Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , .		0
34	O papel dos exames de imagem na avaliaÃ§Ã£o da circulaÃ§Ã£o pulmonar. Jornal Brasileiro De Pneumologia, 2011, 37, 389-403.	0.4	5
35	II Diretriz de AvaliaÃ§Ã£o PerioperatÃ³ria da Sociedade Brasileira de Cardiologia. Arquivos Brasileiros De Cardiologia, 2011, 96, 1-68.	0.3	23
36	Schistosomiasis and others in group 5. , 2011, , 491-499.		0

#	ARTICLE	IF	CITATIONS
37	II Guidelines for perioperative evaluation of the Brazilian Society of Cardiology. Arquivos Brasileiros De Cardiologia, 2011, 96, 1-68.	0.3	29
38	Diagnóstico e tratamento da hipertensão pulmonar: uma atualização. Jornal Brasileiro De Pneumologia, 2010, 36, 795-811.	0.4	26
39	Letter by Dias et al Regarding Article, "Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy". Circulation, 2010, 122, e1.	1.6	1
40	Validação de um protocolo para o teste de caminhada de seis minutos em esteira para avaliação de pacientes com hipertensão arterial pulmonar. Jornal Brasileiro De Pneumologia, 2009, 35, 423-430.	0.4	29
41	Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. Circulation, 2009, 119, 1518-1523.	1.6	176
42	Other Causes of PAH (Schistosomiasis, Porto-Pulmonary Hypertension and Hemolysis-Associated) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	25
43	Corticoide sistêmico como tratamento de primeira linha da hipertensão pulmonar secundária a síndrome POEMS. Jornal Brasileiro De Pneumologia, 2009, 35, 804-808.	0.4	9
44	Aortopulmonary Window: A Rare Cause of Pulmonary Hypertension. Respiration, 2008, 76, 351-352.	1.2	1
45	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 69-75.	1.3	65
46	Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática. Arquivos Brasileiros De Cardiologia, 2006, 87, e195-e197.	0.3	12
47	The Role of NT-proBNP as a Prognostic Marker in Pulmonary Hypertension. Chest, 2006, 130, 1627.	0.4	6
48	The Need for National Registries in Rare Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 228-228.	2.5	9
49	Acute vasodilator test in pulmonary arterial hypertension: Evaluation of two response criteria. Vascular Pharmacology, 2005, 43, 143-147.	1.0	40
50	Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Current Medical Research and Opinion, 2005, 21, 907-911.	0.9	36
51	Resolução do "shunt" direita-esquerda após uso do sildenafil como tratamento de hipertensão pulmonar primária. Jornal De Pneumologia, 2003, 29, 305-308.	0.1	0